PT  - JOURNAL ARTICLE
AU  - Anthony Khoo
AU  - Saadnah Naidu
AU  - Surapi Bhairavi Wijayendran
AU  - Ashirwad Merve
AU  - Fion Bremner
AU  - Meneka Kaur Sidhu
TI  - Progressive myoclonic epilepsy due to rare mitochondrial ND6 mutation, m.14487T>C
AID  - 10.1136/bmjno-2021-000180
DP  - 2021 Jun 01
TA  - BMJ Neurology Open
PG  - e000180
VI  - 3
IP  - 1
4099  - http://neurologyopen.bmj.com/content/3/1/e000180.short
4100  - http://neurologyopen.bmj.com/content/3/1/e000180.full
SO  - BMJ Neurol Open2021 Jun 01; 3
AB  - Introduction Mitochondrial diseases exhibit wide phenotypic heterogeneity, and can present as progressive myoclonic epilepsy.Summary We report a case of adult-onset drug-resistant epilepsy, cortical myoclonus and bilateral optic neuropathies due to m.14487T>C, a rare mitochondrial gene mutation identified on whole-genome sequencing. This mutation, which affects the NADH dehydrogenase 6 (ND6) subunit of the mitochondrial respiratory chain, is most commonly implicated in cases of infantile-onset Leigh syndrome, although a broader phenotypic spectrum including migraine with aura and progressive myoclonic epilepsy have been described. Serial MRI scans over a 2-year period demonstrated the interval development of bihemispheric stroke-like lesions. Giant somatosensory evoked potentials and short-duration myoclonic jerks with craniocaudal spread on surface electromyography were consistent with cortical myoclonus. Optical coherence tomography showed bilateral symmetric thinning of the nerve fibre layer in the papillomacular bundles.Conclusion Whole-genome sequencing can help to provide a definitive diagnosis for mitochondrial disease and should be considered in situations where clinical suspicion remains high despite normal genetic panels or muscle histopathology. Mitochondrial disease can present as adult-onset progressive myoclonic epilepsy, and bilateral optic neuropathies can be a striking feature of ND6 mitochondrial gene mutations. In our case, severe cortical myoclonus affecting speech and swallowing remained highly drug-resistant, however, symptomatic benefit was derived from targeted onabotulinum toxin A injections.All relevant data are included in the article.